CirculationPub Date : 2026-10-27Epub Date: 2026-09-15DOI: 10.1161/CIRCULATIONAHA.125.078812
María Gallego-Delgado, Sandra Milagros Lorenzo Hernández, Soledad García Hernández, Sara Rodríguez-Diego, David Hansoe Heredero-Jung, Emilia Maneiro Pampín, Marlene Pérez-Barbeito, Mónica García Monsalvo, Belén García-Berrocal, Luis M Rincón, María Jesús García-Salgado, María Elena Arnáiz-García, Cristina Álvarez Martínez, Elena Díaz-Peláez, Ana María Merino, Álvaro Roldán, Alfonso Mayorga, Emilse Martínez, María José Ruiz Olgado, Lucía Rodríguez Estévez, Pedro D Perdiguero, Roberto Voces, Ignacio Cruz-González, Pedro L Sánchez, María Isidoro-García, Juan Pablo Ochoa, Eduardo Villacorta, Mario Torrado
{"title":"Natural Missplicing Events Amplified by an Elusive Deep-Intronic <i>MYBPC3</i> Variant Cause Hypertrophic Cardiomyopathy.","authors":"María Gallego-Delgado, Sandra Milagros Lorenzo Hernández, Soledad García Hernández, Sara Rodríguez-Diego, David Hansoe Heredero-Jung, Emilia Maneiro Pampín, Marlene Pérez-Barbeito, Mónica García Monsalvo, Belén García-Berrocal, Luis M Rincón, María Jesús García-Salgado, María Elena Arnáiz-García, Cristina Álvarez Martínez, Elena Díaz-Peláez, Ana María Merino, Álvaro Roldán, Alfonso Mayorga, Emilse Martínez, María José Ruiz Olgado, Lucía Rodríguez Estévez, Pedro D Perdiguero, Roberto Voces, Ignacio Cruz-González, Pedro L Sánchez, María Isidoro-García, Juan Pablo Ochoa, Eduardo Villacorta, Mario Torrado","doi":"10.1161/CIRCULATIONAHA.125.078812","DOIUrl":"10.1161/CIRCULATIONAHA.125.078812","url":null,"abstract":"<p><strong>Background: </strong>Disruption of <i>MYBPC3</i> precursor mRNA splicing is a frequent genetic cause of hypertrophic cardiomyopathy (HCM). Most often, it reflects changes at canonical sites or the creation of novel splice sites. Prediction tools usually prioritize splice variants with lower efficiency when they are distant from canonical sites. These elusive variants may explain HCM in patients considered genotype-negative after DNA testing.</p><p><strong>Methods: </strong>Massively parallel sequencing identified the previously unreported deep-intronic variant <i>MYBPC3</i> c.2308+227G>A in a cohort of genotype-negative patients with HCM from Salamanca, Spain. SpliceAI predicted a benign effect (Δ score, 0.03). However, its recurrent detection prompted us to conduct extensive analyses to investigate its pathogenicity, including genetic testing, clinical assessment, family studies, splicing assays, and haplotype reconstruction.</p><p><strong>Results: </strong>We identified 35 unrelated HCM probands carrying c.2308+227G>A, plus 46 relatives from 27 families, yielding 81 confirmed carriers. Of these, 56 (69%) met diagnostic criteria for HCM (66% male; mean age, 53±15 years). By age 60 years, cumulative penetrance was estimated to be 81% in women and 96% in men. The combined logarithm of the odds score of 5.51 across 20 informative families provided strong evidence of cosegregation. During follow-up of probands, no significant differences were observed in heart failure, arrhythmic events, atrial fibrillation, or mortality when compared with cohorts carrying other pathogenic <i>MYBPC3</i> variants. Blood splicing assays, confirmed in cardiac tissue, showed that c.2308+227G>A disrupts splicing by the use of pre-existing cryptic donor (c.2308+299) and acceptor (c.2309-580) splice sites, generating 2 misspliced mRNAs with partial intron retention or cryptic exon inclusion, which encode truncated proteins. These cryptic sites are the leading natural, unannotated missplicing events in intron 23, and some of the most frequent across the whole <i>MYBPC3</i> precursor mRNA, as revealed by SpliceVault analysis of RNA sequencing databases. This deep-intronic variant does not alter essential splice motifs but promotes the use of pre-existing cryptic sites, likely through gain of splicing regulatory enhancer elements. The identification of a shared haplotype among HCM probands carrying this variant explains its recurrent detection, consistent with an ancient founder effect.</p><p><strong>Conclusions: </strong><i>MYBPC3</i> c.2308+227G>A is a pathogenic splice-altering variant that causes HCM by amplifying natural missplicing events. These background splicing errors help explain how this elusive variant disrupts splicing without creating novel essential splice sites, thereby expanding the known mechanisms by which deep-intronic variants alter <i>MYBPC3</i> splicing and ultimately contribute to HCM pathogenesis. Elusive <i>MYBPC3</i> splice-altering vari","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1700-1717"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13693976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-09-01DOI: 10.1161/CIRCULATIONAHA.125.078585
Phillip J Zhou, Minja Velimirovic, Tian Yu, Vojislav Gligorovski, Nicolas Mathis, Jing Zhao, Quang Vinh Phan, Felicitas Vogd, Jayoung Ryu, Qisheng Pan, Atharva Tyagi, David B Ascher, Gerald Schwank, Luca Pinello, Christopher A Cassa, Richard I Sherwood
{"title":"LDLR Variant Classification Through Activity-Normalized Prime Editing Screening.","authors":"Phillip J Zhou, Minja Velimirovic, Tian Yu, Vojislav Gligorovski, Nicolas Mathis, Jing Zhao, Quang Vinh Phan, Felicitas Vogd, Jayoung Ryu, Qisheng Pan, Atharva Tyagi, David B Ascher, Gerald Schwank, Luca Pinello, Christopher A Cassa, Richard I Sherwood","doi":"10.1161/CIRCULATIONAHA.125.078585","DOIUrl":"10.1161/CIRCULATIONAHA.125.078585","url":null,"abstract":"<p><strong>Background: </strong>Inherited variants in the LDL (low-density lipoprotein) receptor (<i>LDLR</i>) gene are the most common cause of familial hypercholesterolemia, significantly increasing coronary artery disease risk. Early identification of pathogenic <i>LDLR</i> variants enables prompt lipid-lowering therapy and cascade testing of at-risk relatives; however, most <i>LDLR</i> variants observed in the population have uncertain or absent clinical classifications, leaving many patients without actionable information.</p><p><strong>Methods: </strong>We developed the first activity-normalized prime editing screening pipeline to measure the impact of 5184 <i>LDLR</i> coding variants on LDL-cholesterol (LDL-C) uptake. Each prime editing guide RNA is paired with a genotypic outcome reporter to correct for variable editing efficiency, overcoming a key limitation of previous pooled genome editing screens. A statistical framework further improves variant effect estimates by jointly analyzing all missense variants at each amino acid position.</p><p><strong>Results: </strong>We show that prime editing of the reporter construct correlates with endogenous variant installation frequency, validating the activity normalization approach. The resulting scores capture a continuous spectrum of functional effects, robustly separate pathogenic versus benign ClinVar variants, and show concordance with LDL-C levels in UK Biobank participants. We calibrate functional evidence strengths to the American College of Medical Genetics and Genomics/AMP variant interpretation framework, enabling integration into a clinical variant classification workflow. By combining functional, computational, population, and contextual evidence, 322 of 434 <i>LDLR</i> variants currently classified as variants of uncertain significance, conflicting, or absent from ClinVar appear to meet evidence thresholds for reclassification and can be prioritized for expert review, substantially expanding the pool of actionable variant classifications. The screen also reveals a cluster of gain-of-function variants in <i>LDLR</i> class A repeat 5, at least some of which enhance LDL-C uptake through increased apolipoprotein B interaction, with implications for therapeutic genome editing. Last, prime editing uniquely detects splice-altering coding variants missed by cDNA-based screens and pathogenicity predictors, revealing an advantage of endogenous variant installation.</p><p><strong>Conclusions: </strong>Altogether, activity-normalized prime editing provides a scalable framework for <i>LDLR</i> variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1718-1734"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13536972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effectiveness of Nurse-Coordinated, Digital-Supported Collaborative Care Model in Reducing Hospital Stay and Mortality Among Patients With Heart Failure: TIME-HF Cluster RCT (India).","authors":"Panniyammakal Jeemon, Sanjay Ganapathi, Navya Anikkady, Sunaib Ismail, Govindan Unni, Charantharayil Gopalan Bahuleyan, Renukadevi Meera, Rachel Daniel, Stigi Joseph, Justin Paul Gnanaraj, Sunil Pisharody, Rajeev Edakutty, Johny Joseph, Jabir Abdullakutty, Tiny Nair, Thottathan Athira, Mariyam Alex, Alan Jojo, Gopalan Rajendiran, Jayakumar Balakrishnan, Joyal J Kandathil, Madhu Sreedharan, Nalin Kumar Mahesh, Paul Thomas, Vijayan Ganesan, Placid Sebastian, Sajan Ahmad, Salman Salahuddin, Shafeeq Mattummal, Veena Nanjappa, Vijo George, Eapen Punnoose, N Syam, Sivadasanpillai Harikrishnan","doi":"10.1161/CIRCULATIONAHA.126.082490","DOIUrl":"10.1161/CIRCULATIONAHA.126.082490","url":null,"abstract":"<p><strong>Background: </strong>Heart failure with reduced ejection fraction causes high mortality and recurrent hospitalizations in India. We evaluated the effectiveness of the collaborative care model in improving days alive and out of the hospital and overall survival.</p><p><strong>Methods: </strong>We conducted a parallel-group, cluster-randomized controlled trial involving 1507 adults with heart failure with reduced ejection fraction across 22 centers in India (CTRI/2021/11/037797). Centers were randomized 1:1 to the intervention or usual care. Participants were followed up for 2 years. The intervention included risk stratification, lifestyle and pharmacological optimization, and a nurse-coordinated, mobile health-supported disease management program with self-care education, active follow-up, and continuous outpatient monitoring throughout the study period. The primary outcome was days alive and out of the hospital, and all-cause mortality was assessed as a secondary outcome. Days alive and out of the hospital was analyzed with a one-inflated β model. All-cause mortality was analyzed with Cox proportional hazards models adjusted for the clustered study design.</p><p><strong>Results: </strong>Among 1507 participants (752 usual care; 755 intervention), the mean age was 61.9 years, and 77.6% were men. All participants except one completed 24 months of follow-up. Most participants (70%) had low educational attainment; 57.3% lived in rural areas; and ischemic heart disease was the predominant cause (77.4%). Baseline characteristics were comparable between the intervention and usual care groups. In the one-inflated β model, the probability of surviving up to 730 days without hospitalization was 34.7% (95% CI, 31.2%-38.1%) in the usual care group and 46.5% (95% CI, 42.6%-49.9%) in the intervention group. Participants in the intervention group had 78% higher odds of achieving a percent days alive and out of the hospital of exactly 1 (730/730 days) compared with those in the usual care group (odds ratio, 1.78 [95% CI, 1.42-2.23]). There were 201 deaths (26.73%) in the usual care group compared with 163 deaths (21.59%) in the intervention group (risk ratio, 0.80 [95% CI, 0.67-0.97]). In the multivariable Cox proportional hazards model, the intervention group had a 22% lower mortality risk than the usual care group (hazard ratio, 0.78 [95% CI, 0.63-0.95]; <i>P</i>=0.028).</p><p><strong>Conclusions: </strong>A nurse-coordinated, mobile health-supported collaborative care model for heart failure with reduced ejection fraction in India increased the number of days alive and out of hospital, raised the absolute probability of remaining out of hospital by 11.8 percentage points, and reduced all-cause mortality by 22%.</p><p><strong>Registration: </strong>URL: www.ctri.nic.in; Unique identifier: CTRI/2021/11/037797.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1675-1685"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7619626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-08-28DOI: 10.1161/CIRCULATIONAHA.126.082640
Melissa A Daubert, Michael J Blaha
{"title":"Coronary Calcium Regression With Vitamin Supplementation: A Therapeutic Target or Too Good to be True?","authors":"Melissa A Daubert, Michael J Blaha","doi":"10.1161/CIRCULATIONAHA.126.082640","DOIUrl":"10.1161/CIRCULATIONAHA.126.082640","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1669-1671"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-10-26DOI: 10.1161/CIRCULATIONAHA.126.080624
Xiao Yuan, Ke Pan, Sunzhang He
{"title":"Letter by Yuan et al Regarding Article, \"Breast Cancer Reveals Latent <i>BMPR2</i>-Related Susceptibility to Pulmonary Hypertension\".","authors":"Xiao Yuan, Ke Pan, Sunzhang He","doi":"10.1161/CIRCULATIONAHA.126.080624","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.080624","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 17","pages":"e655-e656"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-10-26DOI: 10.1161/CIRCULATIONAHA.126.083435
Bridget M Kuehn
{"title":"Care Pathways to Support People Living With Heart Failure.","authors":"Bridget M Kuehn","doi":"10.1161/CIRCULATIONAHA.126.083435","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083435","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 17","pages":"1751-1752"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-08-28DOI: 10.1161/CIRCULATIONAHA.126.082363
Selma Hasific, Kristian Altern Øvrehus, Anna Mejldal, Susanne Hosbond, Jess Lambrechtsen, Preman Kumarathurai, Damini Dey, Emil Johannes Ravn, Lars Melholt Rasmussen, Oke Gerke, Hans Mickley, Axel Diederichsen
{"title":"Vitamin K<sub>2</sub> and D<sub>3</sub> Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial.","authors":"Selma Hasific, Kristian Altern Øvrehus, Anna Mejldal, Susanne Hosbond, Jess Lambrechtsen, Preman Kumarathurai, Damini Dey, Emil Johannes Ravn, Lars Melholt Rasmussen, Oke Gerke, Hans Mickley, Axel Diederichsen","doi":"10.1161/CIRCULATIONAHA.126.082363","DOIUrl":"10.1161/CIRCULATIONAHA.126.082363","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery calcification (CAC) progression is a strong predictor of cardiovascular events. We investigated whether supplementation with vitamin K<sub>2</sub> and vitamin D<sub>3</sub> reduces CAC progression in patients with severe coronary calcification.</p><p><strong>Methods: </strong>In this multicenter, double-blind, placebo-controlled randomized trial, 400 participants with a CAC score ≥400 Agatston units (AU) were randomly assigned to vitamin K<sub>2</sub> (720 μg/d) plus vitamin D<sub>3</sub> (25 μg/d) or placebo for 24 months. Participants were enrolled from February 2023 to February 2024. Noncontrast cardiac computed tomography was performed at baseline, 12 months, and 24 months. The primary end point was change in CAC score at 24 months. Subgroup analyses by sex and baseline CAC subgroups (400-999 and ≥1000 AU) were performed. Change in plaque composition was assessed in a subset with CAC score <1000 AU who underwent coronary computed tomography angiography at baseline and 24 months.</p><p><strong>Results: </strong>A total of 398 participants (30% women; median age, 71 years) were included. Median baseline CAC was 903 AU, and 44% had CAC ≥1000 AU. In the intention-to-treat analysis, the mean CAC increase was 196 AU (95% CI, 178-214) with vitamin K<sub>2</sub> and D<sub>3</sub> and 248 AU (95% CI, 225-271 AU) with placebo (between-group difference, -52 AU [95% CI, -79 to -24]). The treatment effect was consistent across sex and baseline CAC subgroups. In the 143 participants who underwent coronary computed tomography angiography, there were a similar increase in total plaque volume and no change in noncalcified plaque volume between groups; progression of calcified plaque volume was attenuated in the intervention group (between-group difference, -8 mm<sup>3</sup> [95% CI, -13 to -2]).</p><p><strong>Conclusions: </strong>Among patients with severe CAC, supplementation with vitamin K<sub>2</sub> and vitamin D<sub>3</sub> reduced progression of CAC over 24 months. The reduction in calcification progression was not associated with an increase in noncalcified plaque volume.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT05500443.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1656-1665"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-10-27Epub Date: 2026-10-26DOI: 10.1161/CIRCULATIONAHA.126.081469
Manon Mougin, Clément Jambon-Barbara, Olivier Boucherat, Steeve Provencher, David Montani, Charles Khouri, Sébastien Bonnet, François Potus
{"title":"Response by Mougin et al to Letter Regarding Article, \"Breast Cancer Reveals Latent <i>BMPR2</i>-Related Susceptibility to Pulmonary Hypertension\".","authors":"Manon Mougin, Clément Jambon-Barbara, Olivier Boucherat, Steeve Provencher, David Montani, Charles Khouri, Sébastien Bonnet, François Potus","doi":"10.1161/CIRCULATIONAHA.126.081469","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.081469","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 17","pages":"e661-e662"},"PeriodicalIF":41.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}